These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Pomara N; Bruno D; Sarreal AS; Hernando RT; Nierenberg J; Petkova E; Sidtis JJ; Wisniewski TM; Mehta PD; Pratico D; Zetterberg H; Blennow K Am J Psychiatry; 2012 May; 169(5):523-30. PubMed ID: 22764362 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
9. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
10. Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. Mattsson N; Insel PS; Donohue M; Jagust W; Sperling R; Aisen P; Weiner MW; JAMA Neurol; 2015 May; 72(5):554-60. PubMed ID: 25775167 [TBL] [Abstract][Full Text] [Related]
12. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378 [TBL] [Abstract][Full Text] [Related]
13. Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study. Pomara N; Bruno D; Plaska CR; Ramos-Cejudo J; Osorio RS; Pillai A; Imbimbo BP; Zetterberg H; Blennow K Transl Psychiatry; 2022 Jul; 12(1):301. PubMed ID: 35902554 [TBL] [Abstract][Full Text] [Related]
14. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis. Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998 [TBL] [Abstract][Full Text] [Related]
15. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease. Pan C; Korff A; Galasko D; Ginghina C; Peskind E; Li G; Quinn J; Montine TJ; Cain K; Shi M; Zhang J J Alzheimers Dis; 2015; 45(3):709-19. PubMed ID: 25613100 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677 [TBL] [Abstract][Full Text] [Related]